Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?

by Zacks Equity Research

Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.

    Zacks Equity Research

    Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?

    by Zacks Equity Research

    Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.

      Zacks Equity Research

      What Lies Ahead for Vice ETFs?

      by Zacks Equity Research

      Vice ETFs, which aim to profit from companies involved in alcohol, tobacco or gambling, are gathering steam.

        Zacks Equity Research

        Is a Beat in Store for Alexion (ALXN) This Earnings Season?

        by Zacks Equity Research

        Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

          Sweta Killa headshot

          Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy

          by Sweta Killa

          Let's dig into the earnings picture of the companies that would drive the performance of the popular health care ETFs in the coming days.

            Zacks Equity Research

            Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings?

            by Zacks Equity Research

            Solid prospects in Global Industrial, Global Energy and Global Institutional segments are likely to drive Ecolab's (ECL) Q1 earnings.

              Zacks Equity Research

              Is a Beat in Store for Bristol-Myers (BMY) in Q1 Earnings?

              by Zacks Equity Research

              Bristol-Myers (BMY) is scheduled to report Q1 earnings on Apr 26.

                Zacks Equity Research

                J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

                by Zacks Equity Research

                Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

                  Zacks Equity Research

                  Roche Hemophilia Drug Gets Breakthrough Therapy Designation

                  by Zacks Equity Research

                  The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.

                    Zacks Equity Research

                    The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox

                      Zacks Equity Research

                      5 Drug Stocks Poised to Surpass on Earnings This Quarter

                      by Zacks Equity Research

                      The outlook for the upcoming first-quarter results looks bright.

                        Zacks Equity Research

                        J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance

                        by Zacks Equity Research

                        J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.

                          Zacks Equity Research

                          Shire Sells Oncology Unit Ahead of Takeda's Potential Offer

                          by Zacks Equity Research

                          Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.

                            Zacks Equity Research

                            Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                            by Zacks Equity Research

                            The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                              Zacks Equity Research

                              Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

                              by Zacks Equity Research

                              Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

                                Zacks Equity Research

                                J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store?

                                by Zacks Equity Research

                                The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.

                                  Zacks Equity Research

                                  FDA Prolongs Review Date for AbbVie Endometriosis Candidate

                                  by Zacks Equity Research

                                  The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.

                                    Zacks Equity Research

                                    Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis

                                    by Zacks Equity Research

                                    The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.

                                      Zacks Equity Research

                                      AbbVie's RA Candidate Meets Primary Endpoints in Phase III

                                      by Zacks Equity Research

                                      AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.

                                        Zacks Equity Research

                                        Biogen Cracks the Case With AbbVie for Humira Biosimilar

                                        by Zacks Equity Research

                                        Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.

                                          Zacks Equity Research

                                          Aeglea Initiates Lung Cancer Combination Study With Keytruda

                                          by Zacks Equity Research

                                          Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.

                                            Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                            by Zacks Equity Research

                                            The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                              Zacks Equity Research

                                              Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus

                                              by Zacks Equity Research

                                              Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.

                                                Zacks Equity Research

                                                AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome

                                                by Zacks Equity Research

                                                AbbVie's (ABBV) key lung cancer candidate, Rova-T falls short in a phase II study. AbbVie will not seek accelerated approval of Rova-T in the third-line setting

                                                  Ryan McQueeney headshot

                                                  Why Is AbbVie (ABBV) Stock Crashing Today?

                                                  by Ryan McQueeney

                                                  Shares of pharmaceutical behemoth AbbVie Inc. (ABBV) dropped more than 11% in early morning trading Thursday after the company???s Rova-T program reported disappointing mid-stage results.